Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical has raised capital by issuing 269,833,333 new fully paid ordinary shares at $0.042 each to sophisticated and institutional investors through an institutional placement. The company has confirmed it remains compliant with its continuous disclosure and financial reporting obligations, and that there is no excluded information that would affect the value of these newly issued shares.
The placement strengthens Actinogen’s balance sheet as it advances late-stage clinical programs for its lead drug Xanamem, including the XanaMIA Phase 2b/3 trial and an upcoming open-label extension in Alzheimer’s disease. Successful execution of these trials could enhance Actinogen’s position in the competitive neurodegenerative and neuropsychiatric treatment landscape, with potential implications for long-term shareholder value and future partnering or commercialization opportunities.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Its lead compound, Xanamem (emestedastat), is an oral, first-in-class 11β-HSD1 inhibitor being developed primarily for Alzheimer’s disease, with additional work in treatment-resistant depression and potential future indications such as Fragile X Syndrome.
YTD Price Performance: -29.51%
Average Trading Volume: 6,164,363
Technical Sentiment Signal: Hold
Current Market Cap: A$137.3M
For detailed information about ACW stock, go to TipRanks’ Stock Analysis page.